Now available AXTLE™

AXTLE™ (pemetrexed) is a folate analog metabolic inhibitor indicated:

• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.
• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

Limitations of Use:
AXTLE is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.

• initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. 

Please see full prescribing information here.